Clinical Trial Detail

NCT ID NCT03056599
Title Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Presage Biosciences
Indications

sarcoma

Therapies

Pembrolizumab

Avelumab

interferon gamma

Olaratumab

Trabectedin

Nivolumab

Gemcitabine

Interferon alpha-2b

Doxorubicin

Atezolizumab

Eribulin

Ipilimumab

Durvalumab

Aldesleukin

Bortezomib

Docetaxel

Age Groups: adult senior

No variant requirements are available.